The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells. (2022)
https://pubmed.ncbi.nlm.nih.gov/34665696/

Spondyloarthritis in African Populations Compared to Europeans Living in the United Kingdom. (2020)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314888/?report=classic

The Semantics of ‘Hip Pain’ and its Impact on Clinical Practice in Patient-Reported Outcome Measures (PROMs) of Disease: Results from a Clinical and Radiological Evaluation Cohort. (2020)
https://pubmed.ncbi.nlm.nih.gov/33521570/

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials (2019)
https://pubmed.ncbi.nlm.nih.gov/30156760/

Genetic diagnostic profiling in axial spondyloarthritis: a real world study (2017)
https://pubmed.ncbi.nlm.nih.gov/27749235/

Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA (2017)
https://pubmed.ncbi.nlm.nih.gov/28293446/

Assessment of the current inflammatory back pain criteria in patients with fibromyalgia (2017)
https://pubmed.ncbi.nlm.nih.gov/28281455/

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 (2017)
https://pubmed.ncbi.nlm.nih.gov/27553214/

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial (2017)
https://pubmed.ncbi.nlm.nih.gov/28551073/